SpectRx sells "non-core" SimpleChoice:
This article was originally published in Clinica
In a move to further its cervical cancer treatment programme, SpectRx, of Norcross, Georgia, has announced that it is terminating the sales of all SimpleChoice products and has sold its SimpleChoice insulin pump product line to ICU Medical. "With the company focusing on developing its cervical cancer technology, insulin pumps were no longer core to that strategy," a SpectRx spokesperson told Clinica. SpectRx is currently working towards completing patient enrolment into its pivotal of its cervical cancer test, which aims to eliminate painful Pap and HPV samples and deliver immediate results. ICU, the San Clemente, California-based IV therapy specialist has acquired a majority of the assets of Sterling Medivations, the SpectRx subsidiary that developed SimpleChoice, for an undisclosed fee. ICU's purchase adds to its portfolio of insulin pumps, as it already manufactures and develops the Orbit 90 diabetes infusion set.